Table 5.
The effect of FXIII-B subunit polymorphisms on FXIII activity and antigen concentration.
| Subjects | Wild Type for the Mutation | Carriers of the Mutation | ||||
|---|---|---|---|---|---|---|
| n | FXIII Activity (%) | FXIII Antigen (mg/L) | n | FXIII Activity (%) | FXIII Antigen (mg/L) | |
| p.His95Arg Polymorphism | ||||||
| All | 594 | 103 ± 21 | 22.9 ± 5.0 | 93 | 109 ± 23 † | 24.0 ± 5.1 * |
| CAS−MI− | 202 | 103 ± 20 | 22.9 ± 4.7 | 35 | 112 ± 23 * | 24.3 ± 5.3 |
| CAS+MI− | 189 | 101 ± 22 | 22.6 ± 5.1 | 25 | 107 ± 25 | 23.7 ± 5.5 |
| CAS+MI+ | 180 | 106 ± 22 | 23.4 ± 5.3 | 30 | 107 ± 20 | 23.7 ± 4.3 |
| CAS+ | 369 | 103 ± 22 | 22.9 ± 5.2 | 55 | 107 ± 22 | 23.7 ± 4.9 |
| MI+ | 203 | 105 ± 23 | 23.4 ± 5.3 | 33 | 109 ± 21 | 24.0 ± 4.6 |
| Intron K nt29756 C>G Polymorphism | ||||||
| All | 486 | 106 ± 21 | 23.8 ± 5.0 | 201 | 97 ± 21 ‡ | 21.3 ± 4.7 ‡ |
| CAS−MI− | 158 | 106 ± 21 | 23.9 ± 5.0 | 79 | 100 ± 20 * | 21.8 ± 4.1 † |
| CAS+MI− | 155 | 106 ± 22 | 23.7 ± 5.1 | 59 | 94 ± 21‡ | 20.7 ± 4.9 ‡ |
| CAS+MI+ | 151 | 109 ± 20 | 24.2 ± 4.9 | 59 | 98 ± 24‡ | 21.6 ± 5.5 ‡ |
| CAS+ | 306 | 107 ± 21 | 23.9 ± 5.0 | 118 | 96 ± 22‡ | 21.1 ± 5.2 ‡ |
| MI+ | 173 | 108 ± 21 | 24.1 ± 5.0 | 63 | 99 ± 24† | 21.7 ± 5.3 † |
FXIII levels are expressed as mean ± SD. FXIII levels were adjusted to gender, smoking, serum total cholesterol and plasma fibrinogen levels. The levels of significance were calculated for the difference between wild type individuals and carriers of the respective mutation. CAS+ and CAS−, patients with and without coronary atherosclerosis, respectively; MI+ and MI−, patients with and without a history of myocardial infarction, respectively; n, number of individuals in each subgroup; * p < 0.05, † p < 0.01, ‡ p < 0.001.